Edition:
United States

Evoke Pharma Inc (EVOK.OQ)

EVOK.OQ on NASDAQ Stock Exchange Capital Market

2.48USD
20 Jul 2017
Change (% chg)

$-0.04 (-1.59%)
Prev Close
$2.52
Open
$2.54
Day's High
$2.54
Day's Low
$2.46
Volume
14,971
Avg. Vol
24,580
52-wk High
$4.54
52-wk Low
$1.35

Latest Key Developments (Source: Significant Developments)

Evoke Pharma enters agreement with Rho to submit NDA for Gimoti
Wednesday, 31 May 2017 08:30am EDT 

May 31 (Reuters) - Evoke Pharma Inc :Evoke Pharma enters agreement with Rho to submit NDA for Gimoti.Evoke Pharma Inc - entered into agreement with Rho Inc for submission of its planned new drug application for Gimoti.Evoke Pharma says remain on track to initiate and complete our PK study in second half of this year with our NDA submission by late 2017 or early 2018.  Full Article

Evoke Pharma Q1 loss per share $0.37
Monday, 15 May 2017 04:05pm EDT 

May 15 (Reuters) - Evoke Pharma Inc :Evoke Pharma reports first quarter 2017 results.Q1 loss per share $0.37.Q1 earnings per share view $-0.16 -- Thomson Reuters I/B/E/S.  Full Article

Evoke Pharma presents Gimoti efficacy and safety data from phase 3 trial
Wednesday, 10 May 2017 08:30am EDT 

May 10 (Reuters) - Evoke Pharma Inc : :Evoke Pharma presents Gimoti efficacy and safety data from phase 3 trial as late breaker at digestive disease week 2017.Says safety data from phase 3 trial were consistent with favorable results from previous gimoti studies.Evoke Pharma - based on recent fda discussions, these data are anticipated to be submitted as part of a new drug application for Gimoti.Says trial data was not statistically significant in itt group.Evoke Pharma - patients, which 51pct enrolled in study, responded clinically and statistically significantly better to gimoti than placebo.  Full Article

Evoke Pharma announces collaboration with Spaulding Clinical Research
Tuesday, 18 Apr 2017 08:30am EDT 

April 18 (Reuters) - Evoke Pharma Inc ::Evoke Pharma Inc- announces collaboration with Spaulding Clinical Research for Gimoti comparative exposure pharmacokinetic trial.To complete PK trial in second half of 2017 with NDA submission for Gimoti to follow in late 2017 or early 2018.  Full Article

Meeting with FDA confirms acceptability of Evoke's proposed trial for Gimoti NDA
Tuesday, 4 Apr 2017 08:30am EDT 

Evoke Pharma Inc : Positive type A meeting with FDA confirms acceptability of Evoke Pharma’S proposed comparative exposure PK trial for Gimoti NDA . Positive type a meeting with FDA confirms acceptability of Evoke Pharma’S proposed comparative exposure PK trial for Gimoti NDA . Company believes it will be able to submit NDA for Gimoti by late 2017 or early 2018 . After discussing protocol design of PK trial with FDA, Co plans to incorporate agency's recommendations in final protocol . Pivotal comparative exposure PK trial will be conducted in healthy volunteers to demonstrate bioequivalence of Gimoti to Reglan tablets .Preparing to execute PK trial and expects to have results in second half of 2017.  Full Article

Evoke Pharma Q4 loss per share $0.12
Wednesday, 15 Mar 2017 04:05pm EDT 

Evoke Pharma Inc : Evoke pharma reports fourth quarter and full year 2016 results . Q4 loss per share $0.12 .Q4 earnings per share view $-0.18 -- Thomson Reuters I/B/E/S.  Full Article

Evoke Pharma announces pricing of public offering
Thursday, 16 Feb 2017 08:46am EST 

Evoke Pharma Inc : Evoke Pharma announces pricing of public offering of common stock .Says public offering of 2.41 million common shares priced at $2.90 per share.  Full Article

Evoke Pharma Q2 loss per share $0.41
Monday, 15 Aug 2016 05:00pm EDT 

Evoke Pharma Inc : Q2 earnings per share view $-0.43 -- Thomson Reuters I/B/E/S .Q2 loss per share $0.41.  Full Article

Evoke Pharma Q2 shr loss $0.41
Monday, 15 Aug 2016 04:31pm EDT 

Evoke Pharma Inc : Evoke pharma reports second quarter 2016 results . Q2 shr loss $0.41 . Q2 shr view $-0.43 -- thomson reuters i/b/e/s .Evoke Pharma says "we will continue to work with fda to pursue a path to approval of gimoti".  Full Article

Evoke Pharma announces $10 million registered direct offering
Friday, 29 Jul 2016 03:15pm EDT 

Evoke Pharma Inc : Evoke Pharma announces $10 million registered direct offering priced at-the-market .Says will issue common stock at a purchase price of $3.0825 per share.  Full Article